Skip to contentS
Syndax Pharmaceuticals Inc
S
SNDXSyndax Pharmaceuticals Inc Q2 2026 · 10-Q
Revenue$72.79M$72.79M+91.8% vs Q2 2025 Net Income-$49.36M-$49.36MN/M vs Q2 2025 EPS Diluted-$0.55-$0.55N/M vs Q2 2025 Operating Income-$39,995,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-54.9%+127.8 pt vs Q2 2025
Net margin-67.8%+121.5 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 4, 2026 · 35 d after period end